Search Results 1621-1630 of 21887 for Inhibition

  1. A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer - Mayo Clinic

    Have used a strong cytochrome P450 (CYP) 2C8 inhibitor within 5 elimination half-lives of the inhibitor, or have used a strong CYP3A4 or moderate/strong ...

  2. Neurofibromatosis Type 1 Clinical Trials - Mayo Clinic Research

    ... inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults ...

  3. Knee Reconstruction Clinical Trials - Mayo Clinic Research

    A Study to Evaluate Sex Disparities in Arthrogenic Muscle Inhibition Rochester, MN. Incidence of anterior cruciate ligament (ACL) ruptures ...

  4. Publications - Jason R. Young, M.D. - Mayo Clinic

    Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. ... inhibitor trametinib: a multicenter analysis. Blood ...

  5. Lung Cancer Clinical Trials - Mayo Clinic Research

    PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung ... inhibitor. Pulmonary Rehabilitation Before Lung Cancer Resection ...

  6. Clinical trials - Oncology (Medical)

    ... inhibitor, crizotinib. After enrollment, patients will receive one cycle of Induction chemotherapy. Subsequent therapy will be based upon MIBG avidity and ...

  7. Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER - Mayo Clinic

    ... inhibition of ovulation by oral, implantable, or injectable route of administration;; Intrauterine device (IUD);; Intrauterine hormone-releasing system (IUS); ...

  8. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    as described per protocol. Exclusion Criteria: - History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide ...

  9. A Study To Evaluate Impact Of Efanesoctocog Alfa On Long-term Joint Health In Participants With Hemophilia A - Mayo Clinic

    * Current diagnosis of a FVIII inhibitor, defined as inhibitor titer ≥0.60 BU/mL. "The above information is not intended to contain all considerations ...

  10. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

    ... inhibitors (e.g., crizotinib) appropriate for the treatment of NSCLC in ... inhibition of ovulation together with another additional barrier method ...